This Article Full Text Full Text (PDF) All Versions of this Article: 112/19/3001    most recent CIRCULATIONAHA.105.581892v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zuccollo, A. Articles by Cohen, R. A. Search for Related Content PubMed PubMed Citation Articles by Zuccollo, A. Articles by Cohen, R. A. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Related Collections Type 1 diabetes Mechanism of atherosclerosis/growth factors Animal models of human disease Pathophysiology

(Circulation. 2005;112:3001-3008.)
© 2005 American Heart Association, Inc.

Vascular Medicine

The Thromboxane A₂ Receptor Antagonist S18886 Prevents Enhanced Atherogenesis Caused by Diabetes Mellitus

Adriana Zuccollo, PhD; Chaomei Shi, MD; Roberto Mastroianni, BA; Karlene A. Maitland-Toolan, BS; Robert M. Weisbrod, MA; Mengwei Zang, MD, PhD; Shanqin Xu, MS, MD; Bingbing Jiang, MD, PhD; Jennifer M. Oliver-Krasinski, AB; Antonio J. Cayatte, MD; Stefano Corda, MD, PhD; Gilbert Lavielle, PhD; Tony J. Verbeuren, PhD; Richard A. Cohen, MD

From the Vascular Biology Unit, Department of Medicine, Boston University School of Medicine, Boston, Mass (A.Z., C.S., R.M., K.A.M.-T., R.M.W., M.Z., S.X., B.J., J.M.O.-K., A.J.C., R.A.C.); Institut de Recherches Internationales Servier, Courbevoie, France (S.C.); Division of Chemistry, Institut de Recherches Servier, Croissy, France (G.L.); and Division of Angiology, Institut de Recherches Servier, Suresnes, France (T.J.V.).

Correspondence to Richard A. Cohen, MD, Vascular Biology Unit, X704 Boston University Medical Center, 650 Albany St, Boston, MA 02118. E-mail racohen{at}bu.edu

Received May 4, 2005; de novo received August 9, 2005; accepted August 25, 2005.

Background— S18886 is an orally active thromboxane A₂ (TXA₂) receptor (TP) antagonist in clinical development for use in secondary prevention of thrombotic events in cardiovascular disease. We previously showed that S18886 inhibits atherosclerosis in apolipoprotein E–deficient (apoE^–/–) mice by a mechanism independent of platelet-derived TXA₂. Atherosclerosis is accelerated by diabetes and is associated with increased TXA₂ and other eicosanoids that stimulate TP. The purpose of this study was to determine whether S18886 lessens the enhanced atherogenesis in diabetic apoE^–/– mice.

Methods and Results— Diabetes mellitus was induced in apoE^–/– mice with streptozotocin and was treated or not with S18886 (5 mg · kg^–1 · d^–1). After 6 weeks, aortic lesion area was increased >4-fold by diabetes in apoE^–/– mice, associated with similar increases in serum glucose and cholesterol. S18886 largely prevented the diabetes-related increase in lesion area without affecting the hyperglycemia or hypercholesterolemia. S18886 prevented deterioration of endothelial function and endothelial nitric oxide synthase expression, as well as increases in intimal markers of inflammation associated with diabetes. In human aortic endothelial cells in culture, S18886 also prevented the induction of vascular cell adhesion molecule-1 and prevented the decrease in endothelial nitric oxide synthase expression caused by high glucose.

Conclusions— The TP antagonist inhibits inflammation and accelerated atherogenesis caused by diabetes, most likely by counteracting effects on endothelial function and adhesion molecule expression of eicosanoids stimulated by the diabetic milieu.

Key Words: atherosclerosis • diabetes mellitus • inflammation • nitric oxide synthase • thromboxane

This article has been cited by other articles:

				H. Bayat, S. Xu, D. Pimentel, R. A. Cohen, and B. Jiang Activation of Thromboxane Receptor Upregulates Interleukin (IL)-1 Induced VCAM-1 Expression Through JNK Signaling Arterioscler. Thromb. Vasc. Biol., January 1, 2008; 28(1): 127 - 134. [Abstract] [Full Text] [PDF]

				F. Michel, S. Simonet, C. Vayssettes-Courchay, F. Bertin, P. Sansilvestri-Morel, F. Bernhardt, J. Paysant, J.-S. Silvestre, B. I. Levy, M. Feletou, et al. Altered TP receptor function in isolated, perfused kidneys of nondiabetic and diabetic ApoE-deficient mice Am J Physiol Renal Physiol, January 1, 2008; 294(1): F120 - F129. [Abstract] [Full Text] [PDF]

				J. E. Kanter, F. Johansson, R. C. LeBoeuf, and K. E. Bornfeldt Do Glucose and Lipids Exert Independent Effects on Atherosclerotic Lesion Initiation or Progression to Advanced Plaques? Circ. Res., March 30, 2007; 100(6): 769 - 781. [Abstract] [Full Text] [PDF]

				X. Yi and N. Maeda {alpha}-Lipoic Acid Prevents the Increase in Atherosclerosis Induced by Diabetes in Apolipoprotein E-Deficient Mice Fed High-Fat/Low-Cholesterol Diet. Diabetes, August 1, 2006; 55(8): 2238 - 2244. [Abstract] [Full Text] [PDF]

				L. Gao, F. Wang, B. Wang, B. Gong, J. Zhang, X. Zhang, and J. Zhao Cilostazol Protects Diabetic Rats from Vascular Inflammation via Nuclear Factor-{kappa}B-Dependent Down-Regulation of Vascular Cell Adhesion Molecule-1 Expression J. Pharmacol. Exp. Ther., July 1, 2006; 318(1): 53 - 58. [Abstract] [Full Text] [PDF]

				S. Xu, B. Jiang, K. A. Maitland, H. Bayat, J. Gu, J. L. Nadler, S. Corda, G. Lavielle, T. J. Verbeuren, A. Zuccollo, et al. The Thromboxane Receptor Antagonist S18886 Attenuates Renal Oxidant Stress and Proteinuria in Diabetic Apolipoprotein E-Deficient Mice Diabetes, January 1, 2006; 55(1): 110 - 119. [Abstract] [Full Text] [PDF]